⚠ Evidence warning: Clinical trials or other evidence do not support the claim that nebulized glutathione reduces chronic-sinusitis symptoms, antibiotic use and biofilm burden. This page keeps it as a report of what people, websites or other media say.

Glutathione for Lung Disease (Cystic Fibrosis, COPD, ARDS)

Lung Disease — scientific infographic poster

The lungs are uniquely exposed to oxidative stress — they are the only organ in continuous direct contact with 21% atmospheric oxygen, they receive the entire cardiac output, and they handle inhaled pollutants, allergens, infectious agents, and (in some patients) cigarette smoke. To cope with this constant oxidative burden, the airway maintains glutathione in alveolar lining fluid at concentrations about 140× higher than plasma — the highest extracellular reduced glutathione (GSH) concentration anywhere in the body. In cystic fibrosis, mutant CFTR cannot transport glutathione into the airway lumen, leaving CF patients with airway reduced glutathione levels under 10% of normal and accelerated neutrophil-mediated airway destruction. In chronic obstructive pulmonary disease (COPD), cigarette smoke oxidatively damages the airway epithelium; its effect on airway glutathione is not simple — a 1987 study found that the lung lining fluid of chronic smokers held 80% more total glutathione than that of non-smokers. The PANTHEON trial (Zheng 2014, Lancet Respiratory Medicine) showed N-acetylcysteine (NAC) 600 mg twice daily reduced chronic obstructive pulmonary disease exacerbations by 22% in moderate-to-severe disease. Inhaled glutathione for CF, oral N-acetylcysteine for chronic obstructive pulmonary disease, and adjunctive N-acetylcysteine/reduced glutathione in ARDS together form the major glutathione-targeted interventions in pulmonary medicine.


💥 Interactive Visualization Free Radicals & Your Antioxidant Network Follow one superoxide radical down the whole relay — superoxide dismutase (SOD), catalase, glutathione, vitamin E, vitamin C, reduced nicotinamide adenine dinucleotide phosphate (NADPH) — then release free iron and watch a membrane tear itself apart. Launch →

Table of Contents

  1. Airway Glutathione — About 140× Plasma
  2. Cystic Fibrosis & the CFTR-GSH Transport Defect
  3. Inhaled Glutathione in Cystic Fibrosis
  4. Chronic Obstructive Pulmonary Disease & the Oxidative Burden of Cigarette Smoke
  5. The PANTHEON Trial & BRONCUS
  6. N-Acetylcysteine as Mucolytic — Disulfide Bond Disruption
  7. ARDS & Ventilator-Associated Lung Injury
  8. Idiopathic Pulmonary Fibrosis (IFIGENIA, PANTHER)
  9. Chronic Sinusitis & Nebulized Reduced Glutathione
  10. Asthma & the N-Acetylcysteine Paradox
  11. Doses Used in Trials and Practice, by Condition
  12. Cautions Specific to Pulmonary Patients
  13. Key Research Papers
  14. Connections
  15. Featured Videos

Airway Glutathione — About 140× Plasma

The respiratory epithelium maintains the most concentrated extracellular glutathione environment anywhere in the body. Alveolar lining fluid (the thin liquid film coating the alveolar surface) contains glutathione at concentrations of 100-400 micromolar, compared to plasma levels of 1-3 micromolar. The 1987 study that measured it in healthy volunteers (Cantin) found total glutathione in the lining fluid about 140-fold higher than in the same people's plasma, with 96% of it in the reduced form. The total airway glutathione pool (including the bronchial epithelial cell intracellular reduced glutathione and the airway surface fluid) represents one of the largest organ-system reduced glutathione stores in the body.

This concentration is maintained by active transport of intracellular glutathione (synthesized in alveolar type II cells and bronchial epithelial cells) into the airway lumen via the CFTR chloride channel and the MRP family of efflux transporters. The high airway reduced glutathione is the front-line chemical defense against:

When airway reduced glutathione is depleted — whether through CFTR dysfunction, chronic cigarette smoke exposure, severe acute respiratory inflammation, or systemic reduced glutathione deficiency — the airway epithelium becomes vulnerable to oxidative damage from these same agents. Chronic depletion accelerates airway remodeling, mucus hypersecretion, fibrosis, and progressive airflow obstruction. This is the unifying mechanism underlying CF airway disease, COPD, ARDS, and progressive interstitial lung diseases.

Back to Table of Contents

Cystic Fibrosis & the CFTR-GSH Transport Defect

Cystic fibrosis is the genetic disease that most clearly illustrates the role of glutathione in lung biology. CF is caused by mutations in the CFTR gene encoding the cystic fibrosis transmembrane conductance regulator — an apical-membrane chloride channel expressed in airway, intestinal, biliary, pancreatic, and reproductive epithelia.

The dominant CF mutation (F508del, accounting for ~70% of CF alleles) and other major mutations produce dysfunctional CFTR that cannot transport chloride properly. The downstream consequences are well-known: thick, dehydrated airway mucus that impairs mucociliary clearance, leading to chronic bacterial colonization (Pseudomonas, Staphylococcus, Burkholderia), persistent neutrophilic inflammation, progressive bronchiectasis, and ultimately respiratory failure.

A less widely appreciated function of CFTR is that it also transports glutathione (in addition to chloride). When CFTR is non-functional, glutathione cannot be transported from airway epithelial cells into the airway lumen. The consequence is dramatic:

This reduced glutathione-transport defect is partly independent of the chloride-transport defect. Even with effective mucus clearance and bacterial control, the airway antioxidant deficiency persists and contributes to disease progression. This is the biological rationale for direct airway glutathione delivery in CF: bypass the broken transport mechanism by inhaling glutathione directly into the airway lumen.

For the broader picture of CF management, see our Cystic Fibrosis page.

Back to Table of Contents

Inhaled Glutathione in Cystic Fibrosis

Multiple clinical trials have studied inhaled (nebulized) glutathione as antioxidant therapy in CF. The intervention rationale is straightforward: nebulized reduced glutathione delivers reduced glutathione directly to the airway surface, bypassing the broken CFTR-mediated transport mechanism.

Bishop trial (2005)

An early pilot trial enrolled 19 CF patients aged 6 to 19 to inhaled buffered reduced glutathione (about 66 mg per kg of body weight per day in total, split across four inhalation sessions a day) or placebo for 8 weeks; 9 glutathione and 7 placebo patients made up the final analysis. The glutathione group showed:

Griese trial (2013)

A larger German trial of 153 CF patients tested inhaled glutathione 646 mg every 12 hours for 6 months. The glutathione arm did not show a statistically significant FEV1 improvement over the 6 months (an exploratory analysis found a gain of 100 mL, or 2.2% of predicted, that was significant at 3 months but not later), and had neither fewer lung flare-ups (pulmonary exacerbations) nor better quality-of-life scores. Sputum glutathione rose, showing the drug reached the lungs, but markers of oxidative stress and inflammation did not change; the authors reported no clinically relevant improvements at this dose. Heterogeneity in baseline severity, antibiotic use, and CFTR genotype likely contributed to the diluted effect.

Calabrese trial (2015)

An Italian single-blind trial randomized 105 patients (54 adults, 51 children) to inhaled glutathione or placebo twice daily for 12 months. It did not reach its pre-set goal of a 15% improvement in FEV1%; only patients with moderate lung disease had a statistically significant FEV1 rise from baseline at 3, 6 and 9 months, and the 6-minute walking test improved in the children. Glutathione was well tolerated.

Cochrane review (Ciofu 2019 update)

The 2019 Cochrane systematic review of antioxidants in CF (20 studies, 924 children and adults) found that inhaled glutathione probably improves lung function (FEV1 % predicted) by about 3.5 percentage points at three months, but not significantly at six months (2.3 points). One study of 153 people found no difference in the time to the first lung flare-up (pulmonary exacerbation), and inhaled glutathione probably made little or no difference to quality of life; adverse events were similar to placebo. Oral N-acetylcysteine probably raised FEV1 % predicted by about 4.4 points at six months (two studies, 109 people). Only 1 of the 20 studies was judged free of bias. The authors called for further, better-designed studies before a firm conclusion can be drawn, and noted that the benefit of antioxidants in people taking the newer CFTR modulator drugs has not yet been studied.

Practical use

In current CF practice, inhaled glutathione is not standard of care but is used in some specialized centers as adjunctive therapy. Typical regimen: reduced glutathione 300-600 mg in 3-4 mL saline, nebulized twice daily, prepared by a compounding pharmacy (glutathione must be reduced form, not oxidized, and is air-sensitive). Many CF clinicians prefer oral N-acetylcysteine 600-1200 mg twice daily as a simpler systemic alternative that has shown similar though smaller benefits in some trials.

The arrival of CFTR modulator therapy (elexacaftor/tezacaftor/ivacaftor) has transformed the CF clinical landscape and reduced the relative importance of antioxidant adjuncts. With effective modulator therapy restoring partial CFTR function, airway reduced glutathione transport is partially restored. However, modulators are not curative, and antioxidant adjuncts may still have a role — particularly for the ~10% of CF patients with mutations not addressed by current modulators.

Back to Table of Contents

Chronic Obstructive Pulmonary Disease & the Oxidative Burden of Cigarette Smoke

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, responsible for over 3 million deaths annually. The disease encompasses chronic bronchitis (airway mucus hypersecretion and inflammation), emphysema (destruction of alveolar walls and loss of elastic recoil), and small airway disease — usually overlapping in any given patient.

The primary causal mechanism is cigarette smoke exposure. Each cigarette puff contains approximately 1015-1017 free radicals in the gas phase (semiquinones, peroxyl radicals, nitric oxide) plus quinones, semiquinones, aldehydes (acrolein, formaldehyde), and reactive aromatic compounds in the particulate phase. This oxidative burden:

Even decades after smoking cessation, ex-smokers show persistent reductions in glutathione/cysteine status, ongoing oxidative airway damage markers, and progressive airflow obstruction. The "memory" of cigarette smoke exposure includes a sustained antioxidant deficiency that contributes to continued chronic obstructive pulmonary disease progression.

This is the conceptual basis for the long-running interest in antioxidant supplementation (particularly N-acetylcysteine) as adjunctive therapy in chronic obstructive pulmonary disease. The hypothesis: restore the cellular reduced glutathione pool that smoking has depleted, reduce ongoing oxidative damage, and slow the rate of FEV1 decline.

For the full picture of chronic obstructive pulmonary disease management, see our chronic obstructive pulmonary disease page.

Back to Table of Contents

The PANTHEON Trial & BRONCUS

BRONCUS (Decramer et al., 2005, The Lancet)

The Bronchitis Randomized On N-acetylcysteine Cost-Utility Study was a 3-year randomized double-blind placebo-controlled trial of N-acetylcysteine 600 mg daily vs placebo in 523 chronic obstructive pulmonary disease patients in Europe. The trial had mixed results:

BRONCUS was widely interpreted as a negative trial that dampened enthusiasm for N-acetylcysteine in chronic obstructive pulmonary disease throughout the late 2000s. However, the subgroup signal kept investigator interest alive, and a key insight emerged: the 600 mg/day N-acetylcysteine dose used in BRONCUS may have been too low to produce meaningful airway antioxidant effects.

PANTHEON (Zheng et al., 2014, Lancet Respiratory Medicine)

The Chinese PANTHEON trial (Prevention of Acute exacerbations of chronic bronchitis with N-acetylcysteine randomized HEterogeneity ON) tested N-acetylcysteine at twice the BRONCUS dose: 600 mg twice daily (1200 mg total/day) vs placebo for 1 year, in 1006 moderate-to-severe chronic obstructive pulmonary disease patients:

PANTHEON established 600 mg twice daily as the standard N-acetylcysteine dose for chronic obstructive pulmonary disease and reversed the negative reading of BRONCUS. The mechanism is most likely a combination of:

Following PANTHEON, the GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines updated their recommendations to include N-acetylcysteine 600 mg twice daily as adjunctive therapy for patients with frequent exacerbations, particularly those not on inhaled corticosteroids or with phenotypes suggesting predominant oxidative stress mechanisms.

Back to Table of Contents

N-Acetylcysteine as Mucolytic — Disulfide Bond Disruption

Beyond its glutathione-precursor role, N-acetylcysteine has direct mucolytic activity that is mechanistically independent of the antioxidant pathway. Airway mucus contains mucin glycoproteins (predominantly MUC5AC and MUC5B in healthy airways; MUC5AC dominates in disease states like chronic bronchitis and asthma) cross-linked by disulfide bonds between cysteine residues. The cross-linking is what creates the viscoelastic gel structure of mucus.

The free sulfhydryl group on N-acetylcysteine can directly attack and cleave these mucin disulfide bonds, reducing mucus viscosity and improving the rheological properties. The effect is dose-dependent and dose-related: higher local concentrations produce more mucolysis. This is why nebulized N-acetylcysteine (10-20% solution) is used acutely in cystic fibrosis exacerbations, bronchiectasis with thick secretions, and intubated intensive care unit (ICU) patients with impaired airway clearance.

Oral N-acetylcysteine at the PANTHEON dose (600 mg BID) produces measurable but modest mucolytic effect — some patients report reduced sputum viscosity and easier expectoration. The clinical benefit in chronic obstructive pulmonary disease likely combines this mucolytic effect with the antioxidant effect, with the relative contributions varying by patient phenotype.

Other mucolytic strategies that complement N-acetylcysteine include:

A 2019 Cochrane review of oral mucolytics (N-acetylcysteine, carbocisteine, erdosteine and ambroxol; 38 trials, 10,377 people with chronic bronchitis or COPD) found that people taking a mucolytic were more likely to stay free of flare-ups during the study period (Peto odds ratio 1.73, from 28 studies with 6,723 people): on average, 8 people had to take a mucolytic for about nine months for one extra person to stay flare-up-free. Mucolytics were linked to about 0.43 fewer days of disability per person per month and were not associated with more side effects than placebo. The reviewers noted that longer and more recent studies showed smaller benefits than the earlier ones, and found limited effect on lung function or quality of life.

For chronic bronchitis patients with productive cough and thick sputum, the combination of oral N-acetylcysteine 600 mg BID + adequate hydration + regular airway clearance maneuvers (huff coughing, oscillatory PEP, postural drainage) often substantially reduces sputum burden and improves quality of life.

Back to Table of Contents

ARDS & Ventilator-Associated Lung Injury

Acute respiratory distress syndrome (ARDS) is acute, severe, diffuse alveolar injury from sepsis, pneumonia, aspiration, trauma, or other systemic insults, resulting in non-cardiogenic pulmonary edema, severe hypoxemia, and reduced lung compliance. Intensive care unit mortality remains 30-40% even with optimal supportive care including low-tidal-volume ventilation and prone positioning.

The pathophysiology of ARDS involves massive oxidative damage to the alveolar-capillary barrier. Activated neutrophils release reactive oxygen species, proteases, and inflammatory mediators that disrupt endothelial and epithelial integrity, allowing protein-rich edema fluid to flood the alveolar space. Alveolar lining fluid reduced glutathione is depleted within hours of ARDS onset, removing the primary chemical defense against further oxidative damage.

Multiple small intensive care unit trials have tested intravenous (IV) N-acetylcysteine and intravenous glutathione as adjunctive ARDS therapy:

The clinical synthesis: intravenous N-acetylcysteine has biological plausibility and shows some signal of benefit in ARDS, but the effect size is modest and most studies are small. N-acetylcysteine is not standard of care for ARDS but is used in some intensive care units, particularly for sepsis-related ARDS where the additional anti-inflammatory effects may help. No standard ARDS dose exists; the trials above used 70 mg/kg every 8 hours (Bernard), 190 mg/kg/day (Domenighetti) and 40 mg/kg/day (Suter).

For ventilator-associated lung injury more broadly, the antioxidant rationale extends to all critically ill ventilated patients, but the evidence is even weaker than for ARDS specifically. N-acetylcysteine adjunctive use remains a clinician-by-clinician decision.

Back to Table of Contents

Idiopathic Pulmonary Fibrosis (IFIGENIA, PANTHER)

Idiopathic pulmonary fibrosis (IPF) is a progressive scarring lung disease of unknown cause, with median survival of 3-5 years from diagnosis. Oxidative stress is implicated in the pathobiology: lower airway reduced glutathione is depleted, oxidative damage markers are elevated, and aberrant epithelial-mesenchymal transition (driving fibroblast activation) is partly redox-mediated.

IFIGENIA (Demedts et al., 2005, NEJM)

The first major N-acetylcysteine trial in IPF. 182 patients were randomized to N-acetylcysteine 600 mg three times daily or placebo, each added to standard prednisone + azathioprine therapy, for 12 months; 155 of them formed the main analysis group. The N-acetylcysteine arm showed:

IFIGENIA produced enthusiasm for N-acetylcysteine as part of standard IPF therapy.

PANTHER-IPF (2012, NEJM)

The follow-up PANTHER trial randomized IPF patients to three arms: triple therapy (prednisone + azathioprine + N-acetylcysteine), N-acetylcysteine alone, or placebo. The triple therapy arm was stopped early due to increased mortality and hospitalization in the active treatment group — an unexpected and concerning finding that overturned the prior practice of triple therapy for IPF.

The N-acetylcysteine-monotherapy vs placebo arms continued. Final analysis (2014) showed:

Subgroup analyses

Post-hoc analyses of PANTHER suggested that patients with the TT genotype of the TOLLIP rs3750920 polymorphism may benefit from N-acetylcysteine monotherapy while patients with other genotypes do not. In the 2015 re-analysis (Oldham), N-acetylcysteine was linked to a lower risk of the combined outcome of death, transplant, hospitalization or a fall of 10% or more in FVC in people with the TT genotype (hazard ratio 0.14; P = 0.03), while people with the CC genotype showed a non-significant increase in risk (hazard ratio 3.23; P = 0.10) — a trend toward harm; the pattern was repeated in a separate IPF group. The TT genotype is present in about 25% of people with IPF. This pharmacogenomic finding has not yet been prospectively validated but is being explored in ongoing IPF research: the PRECISIONS trial, whose design was published in 2022, is randomizing 200 people with IPF and the TT genotype to N-acetylcysteine 600 mg three times a day or placebo for 24 months (no results were listed in PubMed as of November 2026).

Current standard of care for IPF is now nintedanib or pirfenidone (anti-fibrotic agents) rather than N-acetylcysteine. N-acetylcysteine is not recommended as standard IPF therapy. Some integrative pulmonologists continue to use N-acetylcysteine adjunctively for patients with documented antioxidant deficiency or with the TOLLIP TT genotype, but this remains exploratory.

Back to Table of Contents

Chronic Sinusitis & Nebulized Reduced Glutathione

Chronic rhinosinusitis (CRS) is persistent inflammation of the paranasal sinus mucosa, often with biofilm formation, fungal colonization, and oxidative damage to the sinus epithelium. Standard treatment combines saline irrigation, intranasal corticosteroids, occasional courses of antibiotics, and (in refractory cases) functional endoscopic sinus surgery.

Nebulized glutathione has been used as adjunctive therapy in chronic sinusitis, typically delivered via specialized sinus nebulizers that produce particle sizes appropriate for sinus penetration rather than alveolar deposition. Practitioners report, from small case series and clinical experience:

Typical regimen: reduced glutathione 100-200 mg in 3-5 mL saline, nebulized via sinus nebulizer once or twice daily. Often combined with topical lactoferrin or xylitol for synergistic antimicrobial effects. The intervention requires compounding pharmacy preparation of fresh reduced glutathione solution (oxidizes within days even refrigerated).

The evidence base is limited (mostly observational and small case series); practitioners describe the safety profile as excellent and their clinical experience as favorable, and use it as an add-on for people whose sinusitis has not responded to standard therapy or who want to reduce antibiotic exposure.

Back to Table of Contents

Asthma & the N-Acetylcysteine Paradox

Asthma shares pathophysiological features with chronic obstructive pulmonary disease — airway inflammation, oxidative stress, and mucus production — and might therefore seem like a natural target for N-acetylcysteine therapy. However, the asthma situation is more complex.

For most asthma patients, the standard of care remains inhaled corticosteroids, long-acting beta-agonists, leukotriene modifiers, and (for severe disease) biologic agents targeting immunoglobulin E (IgE) (omalizumab), IL-5 (mepolizumab, reslizumab), or IL-4/IL-13 (dupilumab). N-acetylcysteine is at most an adjunctive consideration.

Back to Table of Contents

Doses Used in Trials and Practice, by Condition

Chronic Obstructive Pulmonary Disease (moderate-to-severe, frequent exacerbations)

Cystic fibrosis

ARDS (ICU setting, by clinician decision)

Chronic sinusitis (refractory)

Asthma (selected patients)

Idiopathic pulmonary fibrosis

Back to Table of Contents

Cautions Specific to Pulmonary Patients

Back to Table of Contents

Key Research Papers

  1. Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, Yao WZ, Ma LJ, Li X, Raiteri L, Sardina M, Gao Y, Wang BS, Zhong NS (2014). Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respiratory Medicine. — PubMed PMID: 24621680
  2. Decramer M, Rutten-van Mölken M, Dekhuijzen PNR, et al. (2005). Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (BRONCUS): a randomised placebo-controlled trial. The Lancet. — PubMed PMID: 15866309
  3. Demedts M, Behr J, Buhl R, et al.; IFIGENIA Study Group (2005). High-dose acetylcysteine in idiopathic pulmonary fibrosis. New England Journal of Medicine. — PubMed PMID: 16306520
  4. Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ (2012). Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. New England Journal of Medicine. — PubMed PMID: 22607134
  5. Idiopathic Pulmonary Fibrosis Clinical Research Network; Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G (2014). Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. New England Journal of Medicine. — PubMed PMID: 24836309
  6. Oldham JM, Ma SF, Martinez FJ, Anstrom KJ, Raghu G, Schwartz DA, Valenzi E, Witt L, Lee C, Vij R, Huang Y, Strek ME, Noth I; IPFnet Investigators (2015). TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. — PubMed PMID: 26331942
  7. Podolanczuk AJ, Kim JS, Cooper CB, Lasky JA, Murray S, Oldham JM, Raghu G, Flaherty KR, Spino C, Noth I, Martinez FJ; PRECISIONS Study Team (2022). Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial. BMC Pulmonary Medicine. — PubMed PMID: 36514019
  8. Bishop C, Hudson VM, Hilton SC, Wilde C (2005). A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest. — PubMed PMID: 15653998
  9. Griese M, Kappler M, Eismann C, Ballmann M, Junge S, Rietschel E, van Koningsbruggen-Rietschel S, Staab D, Rolinck-Werninghaus C, Mellies U, Köhnlein T, Wagner T, König S, Teschler H, Heuer HE, Kopp M, Heyder S, Hammermann J, Küster P, Honer M, Mansmann U, Beck-Speier I, Hartl D, Fuchs C; Glutathione Study Group; Hector A (2013). Inhalation treatment with glutathione in patients with cystic fibrosis: a randomized clinical trial. American Journal of Respiratory and Critical Care Medicine. — PubMed PMID: 23631796
  10. Ciofu O, Smith S, Lykkesfeldt J (2019). Antioxidant supplementation for lung disease in cystic fibrosis. Cochrane Database of Systematic Reviews. — PubMed PMID: 31580490
  11. Calabrese C, Tosco A, Abete P, Carnovale V, Basile C, Magliocca A, Quattrucci S, De Sanctis S, Alatri F, Mazzarella G, De Pietro L, Turino C, Melillo E, Buonpensiero P, Di Pasqua A, Raia V (2015). Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis. Journal of Cystic Fibrosis. — PubMed PMID: 25458463
  12. Bernard GR, Wheeler AP, Arons MM, et al. (1997). A trial of antioxidants N-acetylcysteine and procysteine in ARDS. Chest. — PubMed PMID: 9228372
  13. Domenighetti G, Suter PM, Schaller MD, Ritz R, Perret C (1997). Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. Journal of Critical Care. — PubMed PMID: 9459113
  14. Suter PM, Domenighetti G, Schaller MD, Laverrière MC, Ritz R, Perret C (1994). N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study. Chest. — PubMed PMID: 8275731
  15. Adhikari N, Burns KE, Meade MO (2004). Pharmacologic therapies for adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database of Systematic Reviews. — PubMed PMID: 15495113
  16. Cantin AM, North SL, Hubbard RC, Crystal RG (1987). Normal alveolar epithelial lining fluid contains high levels of glutathione. Journal of Applied Physiology. — PubMed PMID: 3040659
  17. Gao L, Kim KJ, Yankaskas JR, Forman HJ (1999). Abnormal glutathione transport in cystic fibrosis airway epithelia. American Journal of Physiology — Lung Cellular and Molecular Physiology. — PubMed PMID: 10409237
  18. Rahman I, MacNee W (2000). Oxidative stress and regulation of glutathione in lung inflammation. European Respiratory Journal. — PubMed PMID: 11028671
  19. Poole P, Sathananthan K, Fortescue R (2019). Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. — PubMed PMID: 31107966
  20. Sadowska AM, Manuel-Y-Keenoy B, De Backer WA (2007). Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulmonary Pharmacology & Therapeutics. — PubMed PMID: 16458553

PubMed Topic Searches

  1. PubMed: glutathione lung disease
  2. PubMed: NAC COPD trials
  3. PubMed: inhaled glutathione CF
  4. PubMed: CFTR glutathione transport
  5. PubMed: NAC mucolytic mechanism
  6. PubMed: ARDS NAC oxidative
  7. PubMed: IPF NAC trials

Back to Table of Contents

Connections

Back to Table of Contents